Alzheimer’s disease (AD) and dementia are among the most devastating diseases for individuals, families and communities, and these conditions have no cure. In 2013, dementia affected more than 44.4 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 75.6 million in 2030 and to reach 135.5 million in 2050.
Stemedica International’s AD treatments aim to reduce amyloid pathology and improve cognitive function, thus bringing patients and their families hope that these new therapies will halt progression of the disease. Stemedica International’s unique treatment combines itMSCs, itNSCs and stem cell factors licensed from parent company Stemedica Cell Technologies.
Stemedica International has developed treatments that deliver several advantages over alternative approaches. This is achieved through a unique blend of the company’s own expertise and an exclusive relationship with parent company Stemedica Cell Technologies that leverages its manufacturing process. Stemedica International’s technology comprises strong intellectual-property assets, including numerous issued and pending patents and trade secrets.